H1营收净利双降，交大昂立业绩承压

Core Viewpoint - The company, Jiaoda Onlly (交大昂立), reported a decline in both revenue and net profit for the first half of 2025, alongside being under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations [1][2]. Financial Performance - The company achieved a revenue of 151 million yuan, a year-on-year decrease of 5.77% [1]. - The net profit attributable to shareholders was 2.25 million yuan, down 30.54% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was -2.13 million yuan, indicating an increase in losses compared to the previous year [1]. Business Segments - The main business areas of the company include the research, production, and sales of health products, as well as the operation and management of elderly medical care institutions [1]. - In the 2024 annual report, the revenue contributions from health products, real estate, and medical care businesses were 48.45%, 5.01%, and 45.33%, respectively [1]. Challenges and Legal Issues - The health product segment faced a slight decline due to intensified competition in the domestic probiotic industry and changes in tariff policies in North America [2]. - The medical care segment has encountered issues as various non-profit institutions unilaterally terminated management consulting agreements and refused to pay management fees, leading the company to file lawsuits [2]. - The company received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [2].